Korea United Pharm 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  atorvastatin/Ω-3 fatty acid (UI018) / Korea United Pharm
    PK/PD data, Journal:  Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers. (Pubmed Central) -  Aug 27, 2022   
    The GMRs (90% Cis) for the co-administration at steady state of atorvastatin, 2-OH-atorvastatin, DHA, and EPA were 1.150 (0.990-1.335), 1.301 (1.2707-1.1401), 0.320 (0.243-0.422), and 0.589 (0.487-0.712), respectively. The 90% CIs for most primary endpoints were outside the range of typical bioequivalence, indicating a pharmacokinetic interaction between atorvastatin and omega-3.
  • ||||||||||  atorvastatin/?-3 fatty acid (UI018) / Korea United Pharm
    Enrollment closed, Trial primary completion date:  Study to Evaluate the Safety and PK of UI018 (clinicaltrials.gov) -  Dec 21, 2021   
    P1,  N=44, Active, not recruiting, 
    The 90% CIs for most primary endpoints were outside the range of typical bioequivalence, indicating a pharmacokinetic interaction between atorvastatin and omega-3. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2022 --> Nov 2021
  • ||||||||||  atorvastatin/?-3 fatty acid (UI018) / Korea United Pharm
    New P1 trial:  Study to Evaluate the Safety and PK of UI018 (clinicaltrials.gov) -  Oct 19, 2021   
    P1,  N=44, Recruiting, 
  • ||||||||||  desonide/formoterol (UI030) / Korea United Pharm
    New P2 trial:  ABC: Arformoterol/Budesonide for COVID-19 (clinicaltrials.gov) -  Sep 23, 2021   
    P2,  N=140, Not yet recruiting,